CN101868461B - 合成e1活化酶抑制剂的方法 - Google Patents

合成e1活化酶抑制剂的方法 Download PDF

Info

Publication number
CN101868461B
CN101868461B CN2008801015257A CN200880101525A CN101868461B CN 101868461 B CN101868461 B CN 101868461B CN 2008801015257 A CN2008801015257 A CN 2008801015257A CN 200880101525 A CN200880101525 A CN 200880101525A CN 101868461 B CN101868461 B CN 101868461B
Authority
CN
China
Prior art keywords
hydrogen
protecting group
group
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801015257A
Other languages
English (en)
Chinese (zh)
Other versions
CN101868461A (zh
Inventor
伊恩·阿米蒂奇
埃里克·L·埃利奥特
玛丽安娜·兰斯顿
史蒂文·P·兰斯顿
昆廷·J·麦卡宾
水谷弘竹
马修·斯特林
朱磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to CN201610622354.9A priority Critical patent/CN106243111B/zh
Priority to CN201310356726.4A priority patent/CN103483342B/zh
Publication of CN101868461A publication Critical patent/CN101868461A/zh
Application granted granted Critical
Publication of CN101868461B publication Critical patent/CN101868461B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2008801015257A 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法 Expired - Fee Related CN101868461B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201610622354.9A CN106243111B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法
CN201310356726.4A CN103483342B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96300807P 2007-08-02 2007-08-02
US60/963,008 2007-08-02
US6237808P 2008-01-25 2008-01-25
US61/062,378 2008-01-25
PCT/US2008/009338 WO2009042013A1 (fr) 2007-08-02 2008-08-01 Procédé pour la synthèse d'inhibiteurs de l'enzyme d'activation e1

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201610622354.9A Division CN106243111B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法
CN201310356726.4A Division CN103483342B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法

Publications (2)

Publication Number Publication Date
CN101868461A CN101868461A (zh) 2010-10-20
CN101868461B true CN101868461B (zh) 2013-09-25

Family

ID=40225413

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310356726.4A Expired - Fee Related CN103483342B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法
CN2008801015257A Expired - Fee Related CN101868461B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法
CN201610622354.9A Expired - Fee Related CN106243111B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310356726.4A Expired - Fee Related CN103483342B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610622354.9A Expired - Fee Related CN106243111B (zh) 2007-08-02 2008-08-01 合成e1活化酶抑制剂的方法

Country Status (14)

Country Link
US (3) US8933225B2 (fr)
EP (4) EP2540727B1 (fr)
JP (3) JP5479336B2 (fr)
KR (2) KR101925902B1 (fr)
CN (3) CN103483342B (fr)
AU (1) AU2008305767B2 (fr)
CA (2) CA2695193C (fr)
ES (4) ES2655028T3 (fr)
IL (2) IL203590A (fr)
MX (1) MX2010001126A (fr)
RU (2) RU2553476C2 (fr)
TW (2) TWI426077B (fr)
WO (1) WO2009042013A1 (fr)
ZA (1) ZA201000482B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540727B1 (fr) 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Reactif de sulfamoylation
UA108986C2 (uk) * 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)
JP2013541587A (ja) * 2010-11-05 2013-11-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎｅｄｄ８活性化酵素阻害剤の投与
US9290500B2 (en) * 2012-02-17 2016-03-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CN104072381B (zh) * 2013-03-26 2017-04-12 安徽贝克联合制药有限公司 光学纯氨基醇盐酸盐的制备方法
CA2923752A1 (fr) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur d'enzyme d'activation de la nedd8 et d'agents chimiotherapeutiques
HUE045748T2 (hu) 2014-07-01 2020-01-28 Millennium Pharm Inc Heteroaril vegyületek mint SUMO aktiváló enzimek inhibitorai
US10335411B2 (en) 2014-10-29 2019-07-02 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and radiation
CN104974051A (zh) * 2015-06-30 2015-10-14 苏州开元民生科技股份有限公司 (1S,4R)-cis-4-氨基-2-环戊烯-1-甲醇盐酸盐的合成方法
CN106854208B (zh) * 2016-11-25 2019-04-09 成都柏睿泰生物科技有限公司 肿瘤抑制剂mln4924的合成方法
US11124519B2 (en) 2017-09-21 2021-09-21 Millennium Pharmaceuticals, Inc. Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
KR102018341B1 (ko) * 2018-06-21 2019-09-04 성균관대학교산학협력단 RNF170 및 pUL50을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CA3134613A1 (fr) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composes ciblant prmt5
WO2021241191A1 (fr) * 2020-05-26 2021-12-02 ソニーセミコンダクタソリューションズ株式会社 Dispositif de télémétrie
WO2022112951A1 (fr) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Formes à l'état solide de sel de chlorhydrate de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthyl sulfamate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138433A (en) * 1975-06-26 1979-02-06 Hoechst Aktiengesellschaft Process for preparing 1,2-oxa-phospholanes
US4081455A (en) * 1976-06-02 1978-03-28 Pfizer Inc. 6-Amino-2,2-dimethyl-3-cyanopenams
US4803272A (en) * 1987-02-24 1989-02-07 E. I. Du Pont De Nemours And Company S-modified adenosyl-1,8-diamino-3-thiooctane derivatives
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9205071D0 (en) 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
WO1996007646A1 (fr) 1994-09-09 1996-03-14 The Wellcome Foundation Limited Analogues de nucleosides antiviraux contenant une base benzimidazole substituee fixee a une chaine carbocyclique
US5912356A (en) * 1995-09-11 1999-06-15 Glaxo Wellcome Inc. Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
HUP0100142A3 (en) 1997-12-17 2002-01-28 Biocryst Pharmaceuticals Inc B Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
US6878716B1 (en) * 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
JP2000290201A (ja) * 1998-07-06 2000-10-17 Toray Ind Inc 光学異性体の分割方法
US6379552B1 (en) * 1998-07-06 2002-04-30 Toray Industries, Inc. Method for resolving optical isomers
GB9907082D0 (en) 1999-03-26 1999-05-19 Chirotech Technology Ltd The preparation of carboxylic acid derivatives
CO5261573A1 (es) 1999-11-19 2003-03-31 Novartis Ag Derivados de benzoxa y bezotiazol, compuesto y composicion farmaceutica que los contiene y proceso para la preparacion de la mencionada composicion
US20030045508A1 (en) 1999-12-10 2003-03-06 Daluge Susan Mary (1r,cis)-4-(4-amino-7h-pyrrolo'2,3-i(d) pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives as antiviral
WO2001043731A2 (fr) 1999-12-16 2001-06-21 Alcon, Inc. Inhibiteurs d"adenosine kinase pour le traitement du nerf optique et d"une lesion retinienne
DE60209149T2 (de) * 2001-12-21 2006-10-19 Schering Ag Industriell anwendbares verfahren zur sulfamoylation von alkoholen und von phenolen
CA2488842A1 (fr) 2002-06-17 2003-12-24 Merck & Co., Inc. Derives de nucleosides carbocycliques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
GB0225986D0 (en) * 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US7338957B2 (en) * 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090036448A1 (en) 2004-03-30 2009-02-05 Taisho Pharmecutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
JPWO2005097738A1 (ja) 2004-04-06 2008-02-28 大日本住友製薬株式会社 新規スルホンアミド誘導体
CA2471666C (fr) 2004-06-18 2009-10-13 Apotex Pharmachem Inc. Methode de synthese amelioree d'oxcarbazepine et d'intermediaires connexes
JP5048520B2 (ja) * 2005-02-04 2012-10-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
SG169369A1 (en) * 2006-02-02 2011-03-30 Millennium Pharm Inc Inhibitors of e1 activating enzymes
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ATE485276T1 (de) * 2006-08-08 2010-11-15 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1- aktivierenden enzyme
EP2540727B1 (fr) 2007-08-02 2018-07-25 Millennium Pharmaceuticals, Inc. Reactif de sulfamoylation
UA108986C2 (uk) * 2009-05-14 2015-07-10 Мілленніум Фармасьютікалз, Інк. Кристалічна форма гідрохлориду ((1s,2s,4r)-4-{4-[(1s)-2,3-дигідро-1h-інден-1-іламіно]-7h-піроло[2,3-d]піримідин-7іл}-2-гідроксициклопентил)метилсульфамату (варіанти)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLUMBUS,OHIO,US.59246-82-1,59246-81-0.《DATABASE CA [Online]，STN》.1984,1-2. *
John A. Secrist III et al.(±)-3-(4-Amino-1H-pyrrolo[2,3-d]pyrimidin-1-yl)-5-(hydroxymethyl)-(1α,2α,3β,5β)-1,2-cyclopentanediol,the Carbocyclic Analogue of Tubercidin.《J. Med. Chem.》.1984,第27卷第534-536页. *

Also Published As

Publication number Publication date
CA2949336A1 (fr) 2009-04-02
EP2178880A1 (fr) 2010-04-28
CA2695193C (fr) 2018-07-17
IL251372A0 (en) 2017-05-29
TW201434851A (zh) 2014-09-16
EP2540727A1 (fr) 2013-01-02
EP2546256B1 (fr) 2019-10-09
JP2014015483A (ja) 2014-01-30
ES2684309T3 (es) 2018-10-02
RU2553476C2 (ru) 2015-06-20
ES2655028T3 (es) 2018-02-16
US20090036678A1 (en) 2009-02-05
ES2758027T3 (es) 2020-05-04
CN103483342A (zh) 2014-01-01
US20150353555A9 (en) 2015-12-10
EP2540727B1 (fr) 2018-07-25
EP2546256A3 (fr) 2013-04-17
WO2009042013A1 (fr) 2009-04-02
CN101868461A (zh) 2010-10-20
JP6148594B2 (ja) 2017-06-14
ZA201000482B (en) 2011-07-27
US20150080573A1 (en) 2015-03-19
CA2695193A1 (fr) 2009-04-02
CN106243111A (zh) 2016-12-21
CN103483342B (zh) 2016-08-31
AU2008305767A1 (en) 2009-04-02
CA2949336C (fr) 2018-11-06
EP2540726B1 (fr) 2019-10-09
JP2010535217A (ja) 2010-11-18
EP2178880B1 (fr) 2017-10-04
AU2008305767B2 (en) 2014-07-31
JP2015025009A (ja) 2015-02-05
RU2010107471A (ru) 2011-09-10
MX2010001126A (es) 2010-03-01
EP2546256A2 (fr) 2013-01-16
US20180079755A1 (en) 2018-03-22
ES2757928T3 (es) 2020-04-30
US9802938B2 (en) 2017-10-31
JP5479336B2 (ja) 2014-04-23
TW200922937A (en) 2009-06-01
US10745404B2 (en) 2020-08-18
TWI426077B (zh) 2014-02-11
CN106243111B (zh) 2019-07-23
IL251372B (en) 2018-07-31
EP2540726A1 (fr) 2013-01-02
KR20150064252A (ko) 2015-06-10
IL203590A (en) 2017-03-30
KR101925902B1 (ko) 2018-12-06
RU2015108944A (ru) 2015-08-20
KR20100066475A (ko) 2010-06-17
US8933225B2 (en) 2015-01-13

Similar Documents

Publication Publication Date Title
CN103483342B (zh) 合成e1活化酶抑制剂的方法
AU2013204601B2 (en) Process for the synthesis of E1 activating enzyme inhibitors
HK1178167A (en) Intermediates for the synthesis of e1 activity activating enzyme inhibitors
HK1178160A (en) Sulfamoylating reagent
HK1178895A (en) Process for the synthesis of e1 activating enzyme inhibitors
HK1143592A (en) Process for the synthesis of e1 activating enzyme inhibitors
HK1143592B (en) Process for the synthesis of e1 activating enzyme inhibitors
HK1178895B (en) Process for the synthesis of e1 activating enzyme inhibitors
HK1178167B (en) Intermediates for the synthesis of e1 activity activating enzyme inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211029

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL CO.,LTD.

Address before: Massachusetts, USA

Patentee before: MILLENNIUM PHARMACEUTICALS, Inc.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130925

CF01 Termination of patent right due to non-payment of annual fee